Company intelligence / Profile preview

Royalty Management

New York, New York, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Royalty Pharma does not itself develop or commercialize drugs; it provides capital to biopharma innovators by purchasing or financing royalty streams tied to leading and emerging therapies. At present, its portfolio includes royalties from more than 35 approved/commercial products and 17 development-stage product candidates—including high-profile drugs such as Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Biogen’s Spinraza, and many others.

Modalities: Small moleculeBiologicMonoclonal antibodyRNA therapyCell therapyAntisense oligonucleotideOncolytic virus therapy
Industry: Investors

Partnerships

Collaborates with academic institutions, biotech firms, and major pharmaceutical companies globally through royalty transactions

Beyond the preview

Go deeper on Royalty Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Royalty Management.

Explore the full profile